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Shigellosis is an important public health problem,
especially in developing countries. Antibiotic treatment of
bacterial dysentery, aimed at resolving diarrhea or reducing
its duration, is especially indicated whenever malnutrition is
involved. First-line drugs include ampicillin and trimethoprim-
sulfamethoxazole (TMP-SMX); however, multidrug-resistant
(i.e., resistant to ampicillin, TMP-SMX, and chloramphenicol)
Shigella isolates are ubiquitous (1-3). When epidemiologic
data indicate a rise in resistance, fluoroquinolones may be
used in adults and oral third-generation cephalosporins in
children. Except for a single strain in Calcutta (4), Shigella
have not obtained any extended-spectrum beta-lactamase
(ESBL)(4), even though multidrug-resistance plasmids were
described in this genus as early as the late 1950s (5,6).
A new family of ESBLs, displaying greater affinity for
cefotaxime than ceftazidime (CTX-M), has appeared in
various countries. In Argentina, CTX-M-2 is the most
prevalent ESBL (7) and has been reported in several
enterobacteria (8-10). Although very common in nosocomial
pathogens, it has also been recovered from other enteric
microorganisms (11). We describe our analysis of the first
Shigella sonnei isolate resistant to cefotaxime (CTX) but not
to ceftazidime.
The Study
The isolate was from stool samples from a 6-month-old
girl, seen in the outpatient clinic of Hospital SAMIC Oberá in
northern Argentina. The child had vomiting and laboratory-
confirmed bloody diarrhea approximately 20 days after a 1-
week hospital stay for diarrhea and primary malnutrition.
During the hospital stay, she received gentamicin for 1 week,
but no bacterial enteropathogen was isolated.
The child lived in Oberá, a subtropical area in Misiones
that has no running water. In this region, Shigella spp. is
three times more prevalent than Salmonella spp. and other
enteropathogens as the cause of pediatric diarrhea, and
S. sonnei resistance to ampicillin and TMP-SMX is
approximately 43% and 74%, respectively.
S. sonnei was isolated on eosin-methylene blue agar
plates. The isolate did not produce gas and was hydrogen
sulfide-negative and nonmotile. In triple sugar iron agar, it
was negative for citrate, phenylalanine deaminase, and indol
production. It was methyl-red positive, Voges-Proskauer
negative, ornithine decarboxylase positive, arginine dihydro-
lase negative, lysine decarboxylase negative, and urease
(Christensen) negative. (All media were from Britania,
Argentina.) Confirmatory serotyping was carried out with
antisera from the Instituto Nacional de Microbiología Dr.
Carlos Malbran.
Confirmatory susceptibility tests followed conventional
methods (12,13). Briefly, MICs were determined by the agar
dilution method, using Mueller-Hinton agar (Britania) and
inoculums of 104 CFU per spot; plates were incubated
18 hours at 35°C. Escherichia coli ATCC 25922 and E. coli
ATCC 35218 were included as quality controls. Antibiotics
tested were ampicillin, ampicillin + clavulanate (CLA),
cefoxitin, cefotaxime (CTX), CTX + CLA (CTX/CLA),
ceftazidime, and ceftazidime + CLA (ceftazidime/CLA); a
fixed concentration of 4 µg/mL lithium CLA was used when
combined with beta-lactam drugs. Antimicrobial drugs were
provided by Argentia, Argentina (Ampicillin, CTX), Sigma
Chemical Co., St. Louis, MO, USA (ceftazidime), Roemmers,
Argentina (CLA) and Merck Sharp & Dohme, Argentina
(cefoxitin). MICs were as follows: ampicillin, >1,024 µg/mL;
ampicillin + CLA 16 µg/mL; cefoxitin, 2 µg/mL; CTX, 16 µg/mL;
CTX/CLA,  < 0.063 µg/mL; ceftazidime, 1 µg/mL; and
ceftazidime/CLA, < 0.063 µg/mL.
Resistance to gentamicin, amikacin, and TMP-SMX was
detected by agar diffusion (13); quality controls also included
E. faecalis ATCC 29212.
Conclusions
The presence of an ESBL was confirmed by microbiologic
and biochemical tests using different third-generation
cephalosporins as substrates for the enzymes present in
bacterial sonicates and an iodometric detection system (9). A
microbiologic confirmation test for ESBLs was performed
according to recommendations of the National Committee for
Clinical Laboratory Standards for E. coli and Klebsiella spp.
(13). After isoelectric focusing (9), crude bacterial extracts
rendered two bands that hydrolyzed 500 µg/mL ampicillin
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(isoelectric points 5.4 and 8.2), the latter also active on 1,000
µg/mL ceftriaxone. As this enzyme was likely CTX-M-2 (the
band comigrated with authentic CTX-M-2 samples) and the
first probably corresponded to TEM-1 (or another related
enzyme), plasmid DNA obtained by the method of Birnboin
and Doly (14) was used as the template for polymerase
chain reaction amplification, with specific primers
for CTX-M-2 (blaCTX-M-2 I: 5'-TTAATGATGACTCAGAGCATTC-
3';  blaCTX-M-2  II: 5'-GATACCTCGCTCCATTTATTG-3') and
TEM-1 (blaTEM-1  I: 5'-ATAAAATTCTTGAAGACGAAA-3';
bla TEM-1 II 5'-GACAGTTACCAATGCTTAATCA-3'). Two
fragments of 0.9 kbp and 1.2 kbp were obtained; they showed
100% agreement with theoretical and experimentally
obtained fragments from bona fide CTX-M-2 and TEM-1
producing strains, respectively (8,10).
No resistant Shigella was isolated from the other 124
pediatric patients admitted that month for nonsurgical (85
patients) or surgical reasons (29) nor was a nosocomial
outbreak caused by a third-generation cephalosporin-
resistant enterobacteria detected. The patient recovered. The
isolated microorganism was not the likely cause for the
patient’s first hospitalization as it could not be isolated at that
time. Likely alternatives for its acquisition are 1) intestinal
selection or acquisition of a resistant enterobacterium and in
vivo transference to a freshly acquired Shigella or 2) direct
acquisition of the resistant strain from contaminated water
(not sustained, as no other resistant Shigella was obtained
from the same community in the following year).
These findings, which may portend the spread of serious
resistance in Shigella  throughout Argentina and beyond,
suggest the need for susceptibility testing of all Shigella spp.
whenever financially feasible.
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